Skip to main content

Table 3 In-hospital management in tertiary care hospitals

From: Improved treatment and prognosis after acute myocardial infarction in Estonia: cross-sectional study from a high risk country

  Year 2001 Year 2007 Year 2011 P value for trend
n = 210 n = 327 n = 302
% % %
Medications     
 Aspirin 87.1 94.2 94.4 0.003
 P2Y12-receptor inhibitors 17.1 61.5 70.5 <0.001
 Anticoagulants 89.0 93.0 92.7 0.133
 Glycoprotein IIb/IIIa inh. 12.4 38.8 29.1 <0.001
 Betablockers 79.5 82.6 82.1 0.452
 Nitrates 92.4 78.9 76.2 <0.001
 ACEi/ARB 70.5 74.9 81.1 0.006
 Statins 26.7 67.9 77.2 <0.001
Cardiac catheterization 35.7 78.6 80.8 <0.001
Revascularization 27.6 64.2 73.5 <0.001
 PCI 22.4 61.5 67.9 <0.001
 CABG 5.2 3.7 6.0 0.722
Echocardiography 81.9 85.3 88.4 0.044
Treatment for STEMI n = 130 n = 162 n = 160  
Reperfusion for STEMI 42.3 64.2 63.1 <0.001
 Thrombolysis 35.4 7.4 0.6 <0.001
 Primary PCI 6.9 56.8 62.5 <0.001
Treatment for NSTEMI n = 80 n = 165 n = 142  
 PCI 18.8 47.9 53.5 <0.001
 CABG 7.5 3.6 9.2 0.56
  1. Anticoagulants – low molecular weight heparins/unfractionated heparin/ fondaparinux, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, P2Y12-receptor inhibitors – ticlopidine/clopidogrel/ticagrelol, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, STEMI ST- segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction